-
$600 billion invested in more than 99% failure! Heng Rui attacked the grave of the new drug!
Time of Update: 2021-03-25
Aducanumab's research and development process is like a microcosm of many pharmaceutical companies fighting Alzheimer's.
In 2018, Eli Lilly/AstraZeneca announced the termination of multiple phase III clinical trials of the drug lanabecestat for the treatment of Alzheimer's disease.
-
Customers complained about the loose caps of sterile drugs
Time of Update: 2021-03-25
On March 11, the FDA issued a recall announcement, and the US Saijin Pharmaceuticals voluntarily recalled three batches of injection products.
The recall originated from a customer complaint that indicated the possibility of loosening of the cap seal of the vial, which indicated that the aseptic performance of the product could not be guaranteed.
-
China Resources Sanjiu Director Liu Wentao resigns
Time of Update: 2021-03-25
Due to job changes, Liu Wentao proposed to resign as a director of the company's seventh board of directors and a member of the remuneration and assessment committee of the board of directors.
After Liu Wentao resigned, he did not hold any position in the company.
-
AACR 2021 | Baiji Shenzhou, Corning Jerry, Tianji Bio and other Chinese companies will appear
Time of Update: 2021-03-25
[3] Corning Jerry will announce the clinical research data of PD-L1/CTLA-4 double antibody KN046 combined with paclitaxel in the treatment of triple-negative breast cancer at the AACR 2021 meeting.
-
The World Health Organization approves the emergency use list application for Johnson's single-dose new coronary pneumonia vaccine
Time of Update: 2021-03-25
Johnson & Johnson announced on March 13 that the World Health Organization (WHO) has approved the emergency use list (EUL) application for a single-dose new coronary pneumonia vaccine developed by Johnson & Johnson's Janssen Pharmaceutical Company (hereinafter referred to as "Janssen").
-
Pemetrexed disodium for injection passed the consistency evaluation of generic drugs
Time of Update: 2021-03-25
Injection pemetrexed disodium (Austrian Tiancheng the company developed ® ) in the domestic market in 2009, in combination with cisplatin, for the treatment of locally advanced or metastatic non-squamous cell non-small cell lung cancer or inoperable Malignant pleural mesothelioma; or single agent for the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer patients who have progressed after receiving first-line chemotherapy.
-
Senior Vice President and CMO of Betta Pharmaceuticals resigns
Time of Update: 2021-03-25
Mao Li resigned from the position of director, senior vice president and chief medical officer of the company due to personal reasons.
Mao Li has been handed over well, and his resignation as senior vice president and chief medical officer will not affect the normal operation of the company.
-
Nearly $18 billion in losses in 2020! Where did Comey go after the state-owned capital took over?
Time of Update: 2021-03-25
Since then, until April 30, 2019, investors finally learned through an announcement that Kangmei Pharmaceutical was involved in a "financial fraud case" of nearly 30 billion, shocking the pharmaceutical market!
-
Sichuan Huiyu Pharmaceutical will win $500 million in anti-tumor injections
Time of Update: 2021-03-24
Source: Mi Neiwang database, NMPA Recently, Huiyu Pharmaceutical entered the administrative examination and approval stage with the imitation of bendamustine hydrochloride for injection, which was reported for production in the 3rd category.
-
Xiansheng wins 3 billion large varieties of Roche and 60% of the market is in danger
Time of Update: 2021-03-24
Data source: Mi Neiwang database Medical Network News on March 2 A few days ago, the NMPA official website showed that Simcere's mycophenolate mofetil capsules were approved and deemed to have been reviewed.
-
Yangzijiang's 18 injections will lead the list with 3 billion varieties
Time of Update: 2021-03-24
226 ，3，201930。，228（+），TOP10，18。 ： ，，H+/K+-ATP，、、、-（）。 、、、、，。，2019、、（）30，，，30%；，20%。 13 domestic companies submitted supplementary applications for the consistency evaluation of lansoprazole for injection or reported production under the new classification.
13 domestic companies submitted supplementary applications for the consistency evaluation of lansoprazole for injection or reported production under the new classification.
-
Better enters the contrast agent market!
Time of Update: 2021-03-24
Figure 1: Registration status of iopromide injection declared by Chengdu Better Pharmaceutical Source: CDE official website Figure 2: 2020H1 China's public medical institutions TOP20 brands of terminal contrast agents Source: Mi Nei. com, China's public medical institutions terminal competition pattern According to data from Menet.
-
Zhongsheng returned to A to start listing counseling. Why did Fosun and Yuanda differ in market value by 6 times?
Time of Update: 2021-03-24
According to the announcement, all the stocks to be issued by China Biopharmaceutical on the Sci-tech Innovation Board are new shares, and the funds raised are intended to be used for the development of main business, mergers and acquisitions and integration in the industry, and general working capital.
-
Haizheng Pharmaceuticals is expected to be approved for market in the near near days by copying four classes of apixaban tablets
Time of Update: 2021-03-23
Apixaban tablets reviewed companies Source: Mi Nei Net Consistency Evaluation Database As a blockbuster drug on the list of TOP10 global sales, apixaban tablets have many imitation companies in the domestic market.
-
Minimally Invasive Medical loses 1.2-13 billion yuan in drug balloons
Time of Update: 2021-03-23
2-13 billion yuan Recently, MicroPort Medical issued an announcement that according to the unaudited consolidated financial statements of the board of directors, for the 12 months ended December 31, 2020, it recorded a loss attributable to equity shareholders of approximately US$188 million to US$203 million, which is equivalent to RMB 1.
-
The third domestic product! Kelun Pharmaceutical will win $800 million in large varieties
Time of Update: 2021-03-22
Source: Mi Neiwang database, NMPA Medical Network News, March 10 Recently, Kelun Pharmaceutical entered the administrative examination and approval stage with the imitation of the 4 types of sunitinib malate capsules.
-
Chia Tai Tianqing will take the first copy of lenvatinib
Time of Update: 2021-03-22
Registration application status of Lenvatinib mesylate capsules Source: One-click search on Mi Nei. com At present the domestic market a total of 10 companies submitted cutting imatinib mesylate Oakland 4 of generic capsules listed applications involving CTTQ, Simcere, Qilu Pharmaceutical, Cologne Pharmaceutical, Shijiazhuang Pharmaceutical Group, Yangtze River Pharmaceutical and Ao Saikang Wait.
-
Philips: Executive changes announced
Time of Update: 2021-03-22
Medical Network News on March 11 Philips executive changes Recently, Philips announced that Shz Partovi will succeed Jeroen Tas as Chief Innovation and Strategy Officer, formally join the Philips Executive Committee and report directly to CEO Frans van Houten.
-
Medtron: Major adjustments announced
Time of Update: 2021-03-22
The latest results are announced, the CEO remains optimistic On March 3, according to the information on the Medical Design&Outsourcing website, Martha said he was very pleased with Medtronic’s 2021 fiscal third quarter results.
-
Kelun takes the lead in imitating a star drug targeting over $4 billion
Time of Update: 2021-03-22
com, there are currently 4 domestic companies that have submitted enzalutamide listing applications under the new classification, including Hausen, Kelun, Qilu, and Shenyang Hongqi Pharmaceutical.
com, there are currently 4 domestic companies that have submitted enzalutamide listing applications under the new classification, including Hausen, Kelun, Qilu, and Shenyang Hongqi Pharmaceutical.
